Clinical trials: PTLD
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the…
- Conditions
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
- Trial name
- ALLELE (NCT03394365)
- Testing
- tabelecleucel
- Where
- 71 sites in United States, Australia and 7 more
- Volunteers
- 115 people
- Sponsor
- Pierre Fabre Medicament
PTLD, Epstein Barr Virus (EBV) Infection
Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia
People who have received a solid organ transplant can develop ongoing Epstein-Barr virus (EBV) infection in the blood, which increases the risk of a serious cancer called post-transplant lymphoproliferative disorder (PTLD).
- Conditions
- PTLD, Epstein Barr Virus (EBV) Infection, Solid Organ Transplant
- Trial name
- NCT07614282
- Testing
- Rituximab
- Volunteers
- 28 people
- Sponsor
- Jennifer Amengual
TB - Tuberculosis, PTLD
Intergrated Service Delivery for Lung Health Conditions
The Advancing Lung Health in Zambia project aims to improve access to integrated screening, diagnosis, and management of tuberculosis (TB) and other priority respiratory diseases at community and primary healthcare levels.
- Conditions
- TB - Tuberculosis, PTLD, COPD (Chronic Obstructive Pulmonary Disease), Computer Aided Diagnosis
- Trial name
- TB REACH W11 (NCT07816523)
- Testing
- Intergrated lung health screening, AI-Enabled Cough Sound Screening for Tuberculosis, Post-TB Lung Disease evaluation
- Where
- Zambia
- Volunteers
- 20,300 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.
- Conditions
- Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
- Trial name
- NCT04554914
- Testing
- Tabelecleucel
- Where
- 40 sites in United States, Austria and 5 more
- Volunteers
- 190 people
- Sponsor
- Pierre Fabre Medicament
Long COVID, PTLDs
A Prospective Study to Evaluate the Role of T-Cell Dysfunction in Patients Who Present Symptoms Associated With Long COVID, Lyme Disease and Myalic Encephalomyelitis / Chronic Fatigue Syndrome Using the Vira Immune Fluorospot T Cell Assay
This is a longitudinal observational study recruiting individuals that have attended three clinical sites with symptoms associated with a diagnosis of long COVID, PTLDS or ME/CFS.
- Conditions
- Long COVID, PTLDs, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (ICD-10 G93.3)
- Trial name
- NCT06731179
- Where
- 3 sites in United Kingdom
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- ViraxBio Labs
PTLD
PTLD: Multicentric Retrospective Study
This is a multicentric observational retrospective cohort study of patients with histological diagnosis of PTLD. The aim of the study is to analyze the clinical features and survival of patients who received a PTLD diagnosis with…
- Trial name
- FIL_PTLD (NCT06422715)
- Where
- 21 sites in Italy
- Volunteers
- 241 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
- Conditions
- Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS
- Trial name
- NAVAL-1 (NCT05011058)
- Testing
- Nanatinostat in combination with valganciclovir
- Where
- 62 sites in United States, Australia and 12 more
- Volunteers
- 102 people
- Sponsor
- Viracta Therapeutics, Inc.
EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD)
EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases
In this multi-center open-label, non-randomized phase I/II intervention study three consecutive doses of donor-derived EBV Tscm-CTLs will be administered to 10 patients with treatment-refractory EBV lymphoma, diseases or PTLDs.
- Trial name
- ESPECT (NCT05688241)
- Testing
- Donor-derived ex-vivo expanded EBV Tscm CTL
- Where
- 8 sites in Switzerland
- Volunteers
- 10 people
- Sponsor
- University Hospital, Basel, Switzerland
CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, PTLDs
Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases
This study intends to conduct a prospective single-center open single-arm multi-dose escalation study on therapeutic immunological agent treatment in patients with Lymphoproliferative disease associated with EBV to observe the…
- Trial name
- NCT06666153
- Testing
- EBV immunological agent
- Where
- China
- Volunteers
- 27 people
- Sponsor
- West China Hospital
Lymphoma, Hodgkin Lymphoma
Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma
Whole body diffusion-weighted imaging is a functional magnetic resonance imaging technique that characterizes tissue by probing changes in water diffusion secondary to differences in the tissue microstructure.
- Conditions
- Lymphoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma (Follicular, Diffuse B-cel Lymphoma, PTLD and Mantle Cel Lymphoma)
- Trial name
- NCT01231269
- Testing
- MRI
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and…
- Conditions
- Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Trial name
- NCT02822495
- Testing
- tabelecleucel
- Sponsor
- Atara Biotherapeutics
PTLD, Lymphoid Tumor
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
This is an open label, risk-stratified, sequential treatment, phase 2 study of newly diagnosed post-transplant lymphoproliferative disorders with positive CD20 and CD30 expression.
- Conditions
- PTLD, Lymphoid Tumor, Hematopoietic/Lymphoid Cancer, Plasmacytic Hyperplasia PTLD
- Trial name
- NCT04138875
- Testing
- Rituximab, Brentuximab Vedotin, Bendamustine
- Where
- 2 sites in United States
- Sponsor
- Yale University
EBV Emia and EBV Positive PTLD After Allogenic HSCT
EBV-TCR-T Cells for EB Virus Infection After HSCT
This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of EBV-TCR-T cells in patients with EB virus infection after HSCT.
- Trial name
- NCT04156217
- Testing
- EBV-TCR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hebei Yanda Ludaopei Hospital
PTLD, CAEBV
Low-dose CD20 Monoclonal Antibody Injection in Preemptive Treatment of PTLD in Patients With EBV-HLH/CAEBV
This is a clinical study on the efficacy and safety of low-dose CD20 monoclonal antibody injection in preemptive treatment of EBV positive lymphoproliferative diseases after allo-HSCT in patients with EBV-HLH and CAEBV
- Conditions
- PTLD, CAEBV, HLH
- Trial name
- NCT05258136
- Testing
- low-dose CD20 monoclonal antibody injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Transplant, Adaptive Immunity
CNTRP POSITIVE Study
Adequate control of immunosuppression is critical in preventing graft failure after solid organ transplantation (SOT) and in avoiding life-threatening viral and malignant complications.
- Conditions
- Transplant, Adaptive Immunity, EBV, Medication Adherence
- Trial name
- NCT02318030
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- The Hospital for Sick Children
NonHodgkin Lymphoma, Lymphoproliferative Disorders
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)
Subjects have a type of a lymph node cancer called Non-Hodgkin's Lymphoma (NHL) or lymphoproliferative disease (LPD), which affects their immunity, blood production, and can involve multiple other organs in the body.
- Conditions
- NonHodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Lymphoma, EBV-Related PTLD
- Trial name
- PREVALE (NCT02973113)
- Testing
- EBVST Cells, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Baylor College of Medicine
Heart Transplant, Small Intestine Transplant
Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children
Solid organ transplantation is an important therapeutic option for children with a variety of end stage diseases. However, the same immunosuppressive medications that are required to prevent the child's immune system from…
- Conditions
- Heart Transplant, Small Intestine Transplant, Kidney Transplant, Liver Transplant
- Trial name
- NCT02182986
- Testing
- transplant, Immunosuppressive Drugs
- Where
- 7 sites in United States
- Volunteers
- 944 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Post-transplant Lymphoproliferative Disorder, PTLD
Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
Patients with post transplant lymphoproliferative disorder (PTLD) that have been treated with at least one type of chemotherapy, but whose lymphoma is not responding or coming back after the previous treatment will be asked to…
- Trial name
- NCT03086395
- Testing
- Obinutuzumab
- Sponsor
- Case Comprehensive Cancer Center
PTLD, Posttransplant Lymphoproliferative Disorder
Risk Stratified Sequential Treatment for CD20-positive PTLD
This phase-II trial will investigate the efficacy, safety and the tolerability of a sequential therapy consisting of 4 courses of single agent rituximab followed by 4 courses of R-CHOP chemotherapy in patients with CD20+…
- Trial name
- PTLD-1/3 (NCT00590447)
- Testing
- rituximab monotherapy, sequential R-CHOP
- Where
- 7 sites in Australia, Belgium and 5 more
- Volunteers
- 152 people
- Sponsor
- Charite University, Berlin, Germany
Post-transplant Lymphoproliferative Disease (PTLD), Non Burkitt
Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)
Fludarabine may be of benefit to prevent rejection of grafted solid organs in children during chemo-immunotherapy treatment for post transplant lymphoproliferative diseases (PTLDs).
- Trial name
- FCD-R (NCT01088724)
- Testing
- fludarabine, cyclophosphamide, doxorubicin, rituximab
- Where
- Italy
- Volunteers
- 4 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII